Clinical Trial Update: Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 1]

View source ↗

Summary

This entry notes a Phase 1 clinical trial evaluating ranibizumab for recurrent nosebleeds in patients with hereditary hemorrhagic telangiectasia has been withdr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epistaxis
• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: University of California, San Diego | Conditions: Hereditary Hemorrhagic Telangiectasia (HHT), Nosebleeds | Phase 1 | Status: WITHDRAWN